Questioning the data on outcomes and satisfaction with PNP care. Bedwetting dishonesty can't be justified. Prevalance of autism: What the data show.
Contemporary Pediatrics week in review: School avoidance, updates in AD treatment, and more
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Food Insecurity and the Dangers of Infant Formula Dilution
Early puberty rates increased during the COVID-19 pandemic
In a recent study, increased rates of precocious puberty were observed during the COVID-19 pandemic compared to prior years.
Demystifying Infant Formula
Arcutis submits roflumilast 0.15% sNDA for AD in children 6 years and up
Positive topline results from a pair of identical phase 3 trials support the submission of a supplemental New Drug Application to the FDA for Arcutis Biotherapeutics’ roflumilast cream 0.15%, a once-daily topical to treat mild to moderate atopic dermatitis (AD) in children 6 years or older.
Roflumilast cream 0.05% safe, effective for children aged 2 to 5 years with atopic dermatitis
Based on recent positive phase 3 results, Arcutis Biotherapeutics,. intends to submit a supplemental New Drug Application with the FDA for roflumilast cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years.
2 Clarke Drive Cranbury, NJ 08512